Edition:
United States

Mirati Therapeutics Inc (MRTX.OQ)

MRTX.OQ on NASDAQ Stock Exchange Capital Market

5.15USD
24 Mar 2017
Change (% chg)

$0.05 (+0.98%)
Prev Close
$5.10
Open
$5.15
Day's High
$5.20
Day's Low
$5.07
Volume
9,027
Avg. Vol
36,565
52-wk High
$24.42
52-wk Low
$4.40

Latest Key Developments (Source: Significant Developments)

Mirati therapeutics reports financial results and provides business update for the fourth quarter and full year 2016
Thursday, 9 Mar 2017 04:05pm EST 

Mirati Therapeutics Inc : Mirati therapeutics - following public offering in january, well positioned to achieve 2017 milestones in each of programs with funding into late 2018 . Mirati therapeutics reports financial results and provides business update for the fourth quarter and full year 2016 . Q4 loss per share $0.99 .Q4 earnings per share view $-0.97 -- Thomson Reuters I/B/E/S.  Full Article

Mirati Therapeutics reports Q3 loss per share $0.97
Thursday, 3 Nov 2016 04:10pm EDT 

Mirati Therapeutics Inc - : Mirati Therapeutics reports financial results and provides business update for the third quarter 2016 . Q3 loss per share $0.97 .Q3 earnings per share view $-1.16 -- Thomson Reuters I/B/E/S.  Full Article

Broadfin Capital, LLC reports 5.02 pct passive stake in Mirati Therapeutics
Wednesday, 10 Aug 2016 03:00pm EDT 

Mirati Therapeutics Inc : Broadfin Capital, LLC reports 5.02 pct passive stake in Mirati Therapeutics as of August 8, 2016 - SEC Filing Source - http://bit.ly/2aMdcIv Further company coverage: [MRTX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Mirati Therapeutics reports Q2 loss per share of $1.11
Thursday, 4 Aug 2016 04:01pm EDT 

Mirati Therapeutics Inc : Q2 loss per share $1.11 . Mirati therapeutics reports financial results and provides business update for the second quarter 2016 .Q2 earnings per share view $-1.15 -- Thomson Reuters I/B/E/S.  Full Article

Mirati Therapeutics, Inc announces leadership changes
Wednesday, 23 Mar 2016 08:30am EDT 

Mirati Therapeutics, Inc:Says promotion of Jamie A. Donadio to Senior Vice President and Chief Financial Officer, effective as of March 21, 2016.  Full Article

Mirati Therapeutics Inc Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)
Monday, 21 Dec 2015 08:09am EST 

Mirati Therapeutics Inc:Announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced.Also announced that "glesatinib" is the proposed generic name for MGCD265.  Full Article

Mirati Therapeutics Inc announces interim clinical data from ongoing MGCD516 phase 1 dose escalation study in patients with advanced solid tumors
Monday, 28 Sep 2015 08:00am EDT 

Mirati Therapeutics Inc:Says interim clinical data from ongoing MGCD516 phase 1 dose escalation study in patients with advanced solid tumors.Says MGCD516 is well tolerated with favorable pk profile.MGCD516 was well tolerated; frequently reported adverse events being fatigue, diarrhea, cough, hypertension, nausea and vomiting.No dose limiting toxicity were observed at the 110 mg and 150 mg doses.Says expects to initiate the phase 1b dose expansion cohort of the mgcd516 trial in the fourth quarter of 2015.  Full Article

Mirati Therapeutics announces pricing of public offering of common stock
Tuesday, 15 Sep 2015 08:36pm EDT 

Mirati Therapeutics Inc:Says pricing of an underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $45.00 per share.Gross proceeds from this offering are expected to be approximately $101.3 million.Offering is expected to close on or about Sept. 21.Expects to use the net proceeds for working capital and general and administrative expenses.Citigroup, Barclays and Leerink Partners are acting as joint book-running managers in the offering.  Full Article

More From Around the Web

BRIEF-Broadfin Capital LLC reports 6.90 pct passive stake in Mirati Therapeutics Inc as of Jan 6, 2017

* Broadfin Capital LLC reports 6.90 percent passive stake in Mirati Therapeutics Inc as of January 6, 2017 - Sec Filing Source text (http://bit.ly/2ibJ1uN) Further company coverage: